The diabetes drug glipizide was linked to a higher risk of serious heart problems compared to dipeptidyl peptidase-4, or DPP4, inhibitors in patients with Type 2 diabetes, according to a study published July 14 in JAMA Network Open.
Researchers analyzed data from more than 48,000 patients between 2014 and 2023 across 10 U.S. health systems and two large insurers. The observational study was designed to emulate a clinical trial, comparing patients who added either a sulfonylurea or a DPP4 inhibitor to metformin, according to a report from MedPage Today covering the study.
They found glipizide users had a 9.1% risk of major cardiovascular events over five years, compared to 8.1% for DPP4 users — a 13% relative increase. Experts say the findings raise concerns about glipizide’s safety, especially since newer and safer alternatives exist. Cost, however, may be driving continued use of the drug, which is available for under $50 per year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.